柯萨奇B组病毒疫苗在实验性1型糖尿病小鼠模型中预防病毒诱导的糖尿病
本研究用福尔马林灭活无佐剂CVB1疫苗接种NOD和SOCS1-tg小鼠各三次,评估其诱导中和抗体及预防CVB1感染和病毒诱导糖尿病的效果。疫苗诱导强中和抗体反应,保护小鼠免于病毒血症和胰腺病毒播散;缓冲液对照SOCS1-tg小鼠半数发生糖尿病,而接种疫苗的SOCS1-tg小鼠全部受到保护(p < 0.05)。作者认为该临床前概念验证研究为后续开发疫苗以阐明肠道病毒在人类1型糖尿病中作用的研究提供了基础。
要点
- CVB1疫苗诱导强中和抗体反应,保护NOD和SOCS1-tg小鼠免于病毒血症及胰腺病毒播散。
- 缓冲液对照SOCS1-tg小鼠半数(3/6)感染后发生糖尿病,接种疫苗者全部(7/7)受到保护(p < 0.05)。
- 该临床前概念验证研究为后续开发疫苗以阐明肠道病毒在人类1型糖尿病中作用的研究提供了基础。
核心结论
- CVB1疫苗能有效预防CVB1感染和CVB1诱导的糖尿病。
- 该临床前概念验证研究为后续开发疫苗以阐明肠道病毒在人类1型糖尿病中作用的研究提供了基础。
研究设计与样本
- NOD和SOCS1-tg小鼠分别接种三次福尔马林固定无佐剂CVB1疫苗或缓冲液对照。
- 收集血清用病毒中和试验检测中和抗体。
- 接种疫苗和缓冲液处理的小鼠感染CVB1,用标准蚀斑试验和PCR检测病毒血症和胰腺病毒复制。
- 通过血糖测量监测糖尿病发生,并对福尔马林固定石蜡包埋胰腺进行组织学分析和病毒衣壳蛋白1(VP1)、胰岛素和胰高血糖素免疫染色。
主要发现
- CVB1疫苗在NOD小鼠(n = 8)和SOCS1-tg小鼠(n = 7)中均诱导强中和抗体反应,并保护免于病毒血症和病毒向胰腺播散。
- 缓冲液处理的NOD和SOCS1-tg小鼠在感染后第3天100%发生病毒血症。
- 缓冲液处理的SOCS1-tg小鼠半数(3/6)感染CVB1后发生糖尿病,伴胰岛素阳性β细胞丢失和外分泌胰腺损伤。
- 接种疫苗的SOCS1-tg小鼠全部(7/7)免于病毒诱导的糖尿病,未见β细胞丢失或胰腺破坏迹象(p < 0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Epidemiological studies suggest a role for Coxsackievirus B (CVB) serotypes in the pathogenesis of type 1 diabetes, but their actual contribution remains elusive. In the present study, we have produced a CVB1 vaccine to test whether vaccination against CVBs can prevent virus-induced diabetes in an experimental model. METHODS: NOD and SOCS1-tg mice were vaccinated three times with either a formalin-fixed non-adjuvanted CVB1 vaccine or a buffer control. Serum was collected for measurement of neutralising antibodies using a virus neutralisation assay. Vaccinated and buffer-treated mice were infected with CVB1. Viraemia and viral replication in the pancreas were measured using standard plaque assay and PCR. The development of diabetes was monitored by blood glucose measurements. Histological analysis and immunostaining for viral capsid protein 1 (VP1), insulin and glucagon in formalin-fixed paraffin embedded pancreas was performed. RESULTS: The CVB1 vaccine induced strong neutralising antibody responses and protected against viraemia and the dissemination of virus to the pancreas in both NOD mice (n = 8) and SOCS1-tg mice (n = 7). Conversely, 100% of the buffer-treated NOD and SOCS1-tg mice were viraemic on day 3 post infection. Furthermore, half (3/6) of the buffer-treated SOCS1-tg mice developed diabetes upon infection with CVB1, with a loss of the insulin-positive beta cells and damage to the exocrine pancreas. In contrast, all (7/7) vaccinated SOCS1-tg mice were protected from virus-induced diabetes and showed no signs of beta cell loss or pancreas destruction (p < 0.05). CONCLUSIONS/INTERPRETATION: CVB1 vaccine can efficiently protect against both CVB1 infection and CVB1-induced diabetes. This preclinical proof of concept study provides a base for further studies aimed at developing a vaccine for use in elucidating the role of enteroviruses in human type 1 diabetes.
引用
- Stone VM, Hankaniemi MM, Svedin E, et al. A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes. Diabetologia. 2017. PMID: 29151123. doi:10.1007/s00125-017-4492-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。